Skip to main content
logo
Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.410
-0.015 (-1.05%)
At close: Nov 5, 2026, 4:00 PM EST
1.440
+0.030 (2.13%)
After-hours: Nov 5, 2026, 5:42 PM EST

Innate Pharma Revenue

Innate Pharma had revenue of 5.66M EUR in the half year ending June 30, 2026, a decrease of -54.13%. This brings the company's total for the last twelve months to 9.81M, down -22.38% year-over-year. In the year 2025, Innate Pharma had annual revenue of 9.01M, down -55.25%.

Revenue (ttm)
9.81M EUR
Revenue Growth
-22.38%
P/S Ratio
11.75
Revenue / Employee
81,733 EUR
Employees
120
Market Cap
130.26M USD

Revenue Chart

Chart
* This company reports financials in EUR.

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20259.01M-11.12M-55.25%
Dec 31, 202420.12M-41.52M-67.36%
Dec 31, 202361.64M3.97M6.88%
Dec 31, 202257.67M32.97M133.47%
Dec 31, 202124.70M-45.07M-64.60%
Dec 31, 202069.77M-15.68M-18.35%
Dec 31, 201985.45M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Codexis77.68M
Coherus Oncology50.94M
Foghorn Therapeutics36.74M
Armata Pharmaceuticals5.54M
Humacyte2.12M
Molecular Partners AG856.30K
Compass Therapeutics850.00K
Spruce Biosciences697.00K
Revenue Rankings

IPHA News

More News